SecBot SecBot

ETON

Eton Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001710340 Biotech & Drug Discovery
$50.35 +0.18 (+0.36%)
Oct 27 4:00 PM ET · prev $50.17
Market cap
$1.4B
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$70.00
+39% · range $68.00–78.00
Next earnings
Nov 5
in 9 days
1 year
+172.5%
from $18.48 · Oct 27
30 days
−14.9%
from $59.18
52-week range
$14.35–64.43
−22% from high · low Feb 5
Avg volume 20D
554.5K
Sep 30 spike 1.81M
Short interest
🔒 Subscribers only
Insider net
−$25.4M
0 buyers · 5 sellers · since Feb 3
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 11 reports · 90 days
Balance 2 bearish · 5 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/11 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Eton Pharmaceuticals entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $25.4M.

  • InstitutionsBULLISH

    Q2 2026: 21 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD767,972$27.8M
STATE STREET CORPADD701,786$25.4M
Nuveen, LLCDOUBLED375,707$13.6M
Woodline Partners LPADD310,879$11.3M
MARSHALL WACE, LLPDOUBLED249,182$9.0M
VANGUARD PORTFOLIO MANAGEMENT LLCADD194,591$7.0M
JANE STREET GROUP, LLCADD185,697$6.7M
GOLDMAN SACHS GROUP INCTRIM132,583$4.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +39%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 14, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Aug 14, 2026B. Riley Securities
REITERATE
REITERATEBuy
Aug 14, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 28, 2026Craig-Hallum
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$25.4M
sold · 5 insiders
DateInsiderTypeValue
Oct 6, 2026
Krempa David
Chief Business Officer
SELL$229.4K
Oct 2, 2026
Krempa David
Chief Business Officer
EXERCISE10,522 sh
Aug 28, 2026
MAIER PAUL V
Director
EXERCISE$189.0K
Aug 28, 2026
MAIER PAUL V
Director
SELL$2.1M
Aug 28, 2026
MAIER PAUL V
Director
SELL$811.9K
Aug 28, 2026
MAIER PAUL V
Director
SELL$7.9K
Aug 28, 2026
MAIER PAUL V
Director
EXERCISE$91.4K
Aug 24, 2026
Krempa David
Chief Business Officer
SELL$1.6M

Earnings setup

Estimates
Nov 5
reports in 9 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.43$0.37–$0.50+0.0%$46.4M
Current FY🔒 Fresh data, subscribers only
Next FY$2.55$2.11–$2.99-1.2%$220.4M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Eton Pharmaceuticals entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics for…
8-K — Impact 6/10
Oct 6, 2026 SEC
David Krempa, an officer of Eton Pharmaceuticals, filed a Form 144 on October 6, 2026, indicating intent to sell 4,166…
144 — Impact 2/10
Oct 6, 2026 Insider
Krempa David sold 4,166 shares
Chief Business Officer @ $55.07 ($229.4K)
Oct 2, 2026 Insider
Krempa David acquired via exercise 10,522 shares
Chief Business Officer
Sep 28, 2026 SEC
Eton Pharmaceuticals announced the U.S. commercial launch of IMPAVIDO (miltefosine) capsules, a treatment for…
8-K — Impact 5/10
Sep 28, 2026 Other
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Compan
Aug 28, 2026 Insider
MAIER PAUL V acquired via exercise 50,000 shares
Director @ $3.78 ($189.0K)
Aug 5, 2026 Press
Eton Pharmaceuticals licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
ETON Q3 2026 Earnings Scheduled — 2026-11-05
Mar 29, 2027
FDA decision date
PDUFA: ETON — LIBERVANT in acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy — 2027-03-29
FDA target action date 2027-03-29 for ETON (Eton Pharmaceuticals, Inc.). Drug: LIBERVANT. Indication: acute treatment of intermittent, stereotypic…
Recent
Sep 28, 2026
Press release
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical…
Aug 27, 2026
Press release
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical…
Aug 13, 2026
Earnings date
ETON Q2 2026 Earnings Scheduled — 2026-08-13
Aug 6, 2026
Earnings date
ETON Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
M&A
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical…

SecBot reports

18 filings · 5 press releases · 7 bullish · 4 bearish · 7 neutral
All ETON filing & press-release reports (23)